[go: up one dir, main page]

ES2191358T3 - Uso de un inhibidor de aromatasa en el tratamiento de una disminucion en la relacion de androgenos a estrogenos y de la disinergia entre el detrusor y el esfinter uretral en hombres y metodos para estudiar la disinergia en roedores machos. - Google Patents

Uso de un inhibidor de aromatasa en el tratamiento de una disminucion en la relacion de androgenos a estrogenos y de la disinergia entre el detrusor y el esfinter uretral en hombres y metodos para estudiar la disinergia en roedores machos.

Info

Publication number
ES2191358T3
ES2191358T3 ES98958935T ES98958935T ES2191358T3 ES 2191358 T3 ES2191358 T3 ES 2191358T3 ES 98958935 T ES98958935 T ES 98958935T ES 98958935 T ES98958935 T ES 98958935T ES 2191358 T3 ES2191358 T3 ES 2191358T3
Authority
ES
Spain
Prior art keywords
detrusor
men
decrease
treatment
dynergy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98958935T
Other languages
English (en)
Inventor
Risto Santti
Antti Talo
Tomi Streng
Kaija Halonen
Lauri Kangas
Risto Lammintausta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hormos Medical Corp
Original Assignee
Hormos Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hormos Medical Corp filed Critical Hormos Medical Corp
Application granted granted Critical
Publication of ES2191358T3 publication Critical patent/ES2191358T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)

Abstract

El uso de un inhibidor de aromatasa para la fabricación de una composición farmacéutica que es para usar en el tratamiento de la disinergia entre el detrusor y el esfínter uretral en hombres, en el que dicha disinergia entre el detrusor y el esfínter uretral es una disfunción uretral que es debida a una disminución de la razón entre andrógeno a estrógeno en el paciente.
ES98958935T 1997-12-12 1998-12-09 Uso de un inhibidor de aromatasa en el tratamiento de una disminucion en la relacion de androgenos a estrogenos y de la disinergia entre el detrusor y el esfinter uretral en hombres y metodos para estudiar la disinergia en roedores machos. Expired - Lifetime ES2191358T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/989,447 US5972921A (en) 1997-12-12 1997-12-12 Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men

Publications (1)

Publication Number Publication Date
ES2191358T3 true ES2191358T3 (es) 2003-09-01

Family

ID=25535123

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98958935T Expired - Lifetime ES2191358T3 (es) 1997-12-12 1998-12-09 Uso de un inhibidor de aromatasa en el tratamiento de una disminucion en la relacion de androgenos a estrogenos y de la disinergia entre el detrusor y el esfinter uretral en hombres y metodos para estudiar la disinergia en roedores machos.

Country Status (17)

Country Link
US (2) US5972921A (es)
EP (1) EP1043993B1 (es)
JP (1) JP2002508322A (es)
KR (1) KR20010032909A (es)
CN (1) CN1281361A (es)
AT (1) ATE235904T1 (es)
AU (1) AU743196B2 (es)
BR (1) BR9813534A (es)
CA (1) CA2312347A1 (es)
DE (1) DE69813025T2 (es)
EE (1) EE200000346A (es)
ES (1) ES2191358T3 (es)
HU (1) HUP0100762A3 (es)
NO (1) NO20002960L (es)
NZ (1) NZ504632A (es)
PL (1) PL341653A1 (es)
WO (1) WO1999030708A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972921A (en) 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
DE50016101D1 (de) * 1999-08-13 2011-06-09 Curadis Gmbh Substanzen und mittel zur positiven beeinflussung von kollagen
US20030083342A1 (en) * 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds
IL152081A0 (en) * 2000-04-12 2003-05-29 Novartis Ag Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
FI20010905A0 (fi) * 2001-05-02 2001-05-02 Vetcare Oy Uusi eläinlääke
US6607755B2 (en) * 2001-06-21 2003-08-19 Michael Donald Farley Anti-aromatase pharmaceutical composition for controlling testosterone/estrone ratios
US6931276B2 (en) * 2002-04-29 2005-08-16 Tomi Streng Method and device for use in micturition studies
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
WO2005018562A2 (en) * 2003-08-22 2005-03-03 University Of Virginia Patent Foundation Blockade of mtor to prevent a hormonal adaptive response
EP2029128B1 (en) * 2006-05-22 2015-08-05 Hormos Medical Ltd. Method of treatment of chronic nonbacterial prostatitis with selective estrogen receptor modulators or aromatase inhibitors
EP2753312B1 (en) * 2011-09-08 2016-12-14 Mereo BioPharma 2 Limited Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases
CN102641502A (zh) * 2012-04-25 2012-08-22 中国农业大学 芳香酶抑制剂的新用途
EP3120859B1 (en) * 2014-03-21 2023-05-24 Dong Wha Pharm. Co., Ltd. Composition for preventing, treating, and alleviating urinary disturbances, containing piper longum l. extract

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2273704B (en) * 1992-12-16 1997-01-22 Orion Yhtymae Oy Triazolyl diaryl selective aromatase inhibiting compounds
DE4435368A1 (de) 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US5972921A (en) 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men

Also Published As

Publication number Publication date
US6316431B1 (en) 2001-11-13
EP1043993A2 (en) 2000-10-18
JP2002508322A (ja) 2002-03-19
HUP0100762A3 (en) 2002-12-28
US5972921A (en) 1999-10-26
PL341653A1 (en) 2001-04-23
EE200000346A (et) 2001-10-15
HUP0100762A2 (hu) 2001-08-28
NO20002960D0 (no) 2000-06-09
AU1489799A (en) 1999-07-05
ATE235904T1 (de) 2003-04-15
NO20002960L (no) 2000-08-14
BR9813534A (pt) 2000-11-14
KR20010032909A (ko) 2001-04-25
EP1043993B1 (en) 2003-04-02
DE69813025D1 (de) 2003-05-08
CA2312347A1 (en) 1999-06-24
NZ504632A (en) 2001-10-26
WO1999030708A2 (en) 1999-06-24
WO1999030708A3 (en) 1999-08-19
DE69813025T2 (de) 2004-01-15
AU743196B2 (en) 2002-01-24
CN1281361A (zh) 2001-01-24

Similar Documents

Publication Publication Date Title
ES2191358T3 (es) Uso de un inhibidor de aromatasa en el tratamiento de una disminucion en la relacion de androgenos a estrogenos y de la disinergia entre el detrusor y el esfinter uretral en hombres y metodos para estudiar la disinergia en roedores machos.
ATE370730T1 (de) Pharmazeutische zubereitungen, die chelatbildner/sequestriermittel enthalten und deren dermatologische verwendung
CO5150154A1 (es) Composicion de sustrato y metodo para usarlo para el secuestro de irritantes de la piel
DE69826644D1 (de) Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
BR0109925A (pt) Composição de revestimento para mascaramento de paladar
CO5680108A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
PA8638601A1 (es) Regimenes y kits de progestina ciclica
DE50312034D1 (de) Liposomale glucocorticoide
PL357944A1 (en) Intradermal-penetration agents for topical local anesthetic administration
NO20032181L (no) Anvendelse av CCI-779 som et antineoplastisk middel
TR199901669T2 (xx) Erkeklerdeki ereksiyon probleminin tedavisi i�in gerekli dozaj �ekilleri ve metod.
ATE332129T1 (de) Behandlung der akne mit lipoxygenase inhibitoren
PT1267832E (pt) Sistema auto-emulsionante de libertacao de farmaco
CL2004000026A1 (es) Uso de una composicion que comprende 0 a alrededor de 29% de cis-clomifeno y de alrededor de 100 a alrededor de 71% de trans-clomifeno para preparar un medicamento util para aumentar los niveles de testosterona en suero en un mamifero masculino.
AP2003002716A0 (en) Medicinal compositions containing propenone derivatives.
HUP9901360A2 (hu) Cimicifuga racemosa-ból származó extraktum alkalmazása
BR0210101A (pt) Combinações antineoplásticas
AR029092A1 (es) Composiciones para el tratamiento del cabello
AR034071A1 (es) Combinaciones antineoplasicas
ATE324112T1 (de) Topische behandlung bei der mastalgie
DE60017281D1 (de) Nomegestrol acetat und estrogen enthaltende zusammensetzung und ihre verwendung
CO5680386A2 (es) Tirita para refrescar el aliento, mejorada por enzimas
HUP9901505A2 (hu) Dehidroepiandroszteron és aromatázgátlók kombinációja és e kombináció felhasználása férfiak relatív és abszolút androgénhiányának kezelésére szolgáló gyógyszerkészítmények előállítására
AR043013A1 (es) Composicion farmaceutica destinada al tratamiento de la endometriosis
CO5060466A1 (es) Metodo de reduccion o prevencion del mal olor